Kura Oncology, Inc. (KURA)
NASDAQ: KURA · Real-Time Price · USD
15.91
-0.05 (-0.31%)
At close: Nov 20, 2024, 4:00 PM
14.20
-1.71 (-10.75%)
Pre-market: Nov 21, 2024, 4:17 AM EST

Kura Oncology Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 2018 - 2014
Period Ending
Sep '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 2018 - 2014
Selling, General & Admin
67.2750.5747.0546.5431.519.65
Upgrade
Research & Development
150.23115.2492.8184.7260.447.83
Upgrade
Operating Expenses
217.5165.8139.87131.2691.967.48
Upgrade
Operating Income
-217.5-165.8-139.87-131.26-91.9-67.48
Upgrade
Interest Expense
-1.61-1.55-0.23-0.41-0.58-0.58
Upgrade
Interest & Investment Income
12.145.35.865.63.263.82
Upgrade
EBT Excluding Unusual Items
-206.97-162.05-134.23-126.08-89.22-64.24
Upgrade
Gain (Loss) on Sale of Investments
9.429.42-1.61-4.39-0.411.1
Upgrade
Pretax Income
-197.55-152.63-135.84-130.47-89.63-63.14
Upgrade
Net Income
-197.55-152.63-135.84-130.47-89.63-63.14
Upgrade
Net Income to Common
-197.55-152.63-135.84-130.47-89.63-63.14
Upgrade
Shares Outstanding (Basic)
847367665342
Upgrade
Shares Outstanding (Diluted)
847367665342
Upgrade
Shares Change (YoY)
18.20%9.31%0.96%25.01%26.54%19.20%
Upgrade
EPS (Basic)
-2.36-2.08-2.03-1.97-1.69-1.51
Upgrade
EPS (Diluted)
-2.36-2.08-2.03-1.97-1.69-1.51
Upgrade
Free Cash Flow
-169.24-124.99-110.69-105.7-72-54.76
Upgrade
Free Cash Flow Per Share
-2.02-1.71-1.65-1.59-1.36-1.31
Upgrade
EBITDA
-216.64-164.96-139.11-130.7-91.71-67.47
Upgrade
D&A For EBITDA
0.860.850.760.560.190.01
Upgrade
EBIT
-217.5-165.8-139.87-131.26-91.9-67.48
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.